Home › Calculator › CELU Dividend Calculator 2026
CELU Dividend DRIP Calculator 2026
250.00% YieldHealthcareCelularity Inc. · NASDAQ
Price: $0.80 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When CELU pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your CELU snowball 📈
$10,000 in CELU → $4885171282167413.00M in 10 years · $406,938,646,438,519,400,000.00/month
About Celularity Inc. (CELU) — Dividend Analysis 2026
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Compare CELU with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full CELU DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CELU position with:
🌍 CELU Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CELU.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 250.00% | 247.20% | $25,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 212.50% | 209.70% | $21,250 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 200.00% | 197.20% | $20,000 / yr |
| 🇬🇧 UK ISA | 0% | 250.00% | 247.20% | $25,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 228.13% | 225.32% | $22,813 / yr |
| 🇨🇦 TFSA | 0% | 250.00% | 247.20% | $25,000 / yr |
| 🇨🇦 CA Taxable | 25% | 187.50% | 184.70% | $18,750 / yr |
| 🇦🇺 Super (pension) | 15% | 212.50% | 209.70% | $21,250 / yr |
| 🇦🇺 AU Taxable | 30% | 175.00% | 172.20% | $17,500 / yr |
| 🇩🇪 DE Taxable | 26.375% | 184.06% | 181.26% | $18,406 / yr |
| 🇫🇷 FR Taxable | 30% | 175.00% | 172.20% | $17,500 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CELU Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CELU Dividend Payment Schedule
CELU pays quarterly — 4 times per year. Next ex-div: TBD.
📊 CELU vs Healthcare Benchmarks
How CELU compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CELU sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CELU Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| J-Other | 2026-06-19 | 1,204,819 | $1.66 | $2.00M | ||
| J-Other | 2026-06-19 | 839,160 | $2.00 | $1.68M | ||
| J-Other | 2026-06-19 | 1,204,819 | $1.66 | $2.00M | ||
| J-Other | 2026-06-19 | 839,160 | $2.00 | $1.68M | ||
| J-Other | 2026-06-19 | 1,204,819 | $1.66 | $2.00M | ||
| J-Other | 2026-06-19 | 839,160 | $2.00 | $1.68M | ||
| Other | 2025-12-19 | 1,204,819 | $1.66 | $2.00M | ||
| Other | 2026-06-19 | 839,160 | $2.00 | $1.68M | ||
| Other | 2025-12-19 | 1,204,819 | $1.66 | $2.00M | ||
| Other | 2026-06-19 | 839,160 | $2.00 | $1.68M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CELU dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Celularity Inc. (CELU) is currently trading at $0.80, 99% below its 52-week high. The current dividend yield is 250.00% based on an annual payout of $2.00 per share.
CELU (Celularity Inc.) — 250.00% Dividend Yield Analysis
Celularity Inc. (CELU) is a healthcare stock currently trading at $0.80 with a dividend yield of 250.00%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (250.00%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.